238 related articles for article (PubMed ID: 22100984)
21. A novel Aurora kinase A inhibitor MK-8745 predicts TPX2 as a therapeutic biomarker in non-Hodgkin lymphoma cell lines.
Chowdhury A; Chowdhury S; Tsai MY
Leuk Lymphoma; 2012 Mar; 53(3):462-71. PubMed ID: 21879811
[TBL] [Abstract][Full Text] [Related]
22. AT9283, a novel aurora kinase inhibitor, suppresses tumor growth in aggressive B-cell lymphomas.
Qi W; Liu X; Cooke LS; Persky DO; Miller TP; Squires M; Mahadevan D
Int J Cancer; 2012 Jun; 130(12):2997-3005. PubMed ID: 21796626
[TBL] [Abstract][Full Text] [Related]
23. Comparing Aurora A and Aurora B as molecular targets for growth inhibition of pancreatic cancer cells.
Warner SL; Munoz RM; Stafford P; Koller E; Hurley LH; Von Hoff DD; Han H
Mol Cancer Ther; 2006 Oct; 5(10):2450-8. PubMed ID: 17041088
[TBL] [Abstract][Full Text] [Related]
24. MK-5108, a highly selective Aurora-A kinase inhibitor, shows antitumor activity alone and in combination with docetaxel.
Shimomura T; Hasako S; Nakatsuru Y; Mita T; Ichikawa K; Kodera T; Sakai T; Nambu T; Miyamoto M; Takahashi I; Miki S; Kawanishi N; Ohkubo M; Kotani H; Iwasawa Y
Mol Cancer Ther; 2010 Jan; 9(1):157-66. PubMed ID: 20053775
[TBL] [Abstract][Full Text] [Related]
25. Update on aurora kinase inhibitors in gynecologic malignancies.
Tao X; Chon HS; Fu S; Kavanagh JJ; Hu W
Recent Pat Anticancer Drug Discov; 2008 Nov; 3(3):162-77. PubMed ID: 18991785
[TBL] [Abstract][Full Text] [Related]
26. Aurora B kinase inhibition in mitosis: strategies for optimising the use of aurora kinase inhibitors such as AT9283.
Curry J; Angove H; Fazal L; Lyons J; Reule M; Thompson N; Wallis N
Cell Cycle; 2009 Jun; 8(12):1921-9. PubMed ID: 19440047
[TBL] [Abstract][Full Text] [Related]
27. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.
Benten D; Keller G; Quaas A; Schrader J; Gontarewicz A; Balabanov S; Braig M; Wege H; Moll J; Lohse AW; Brummendorf TH
Neoplasia; 2009 Sep; 11(9):934-44. PubMed ID: 19724687
[TBL] [Abstract][Full Text] [Related]
28. Aurora A and B kinases--targets of novel anticancer drugs.
Libertini S; Abagnale A; Passaro C; Botta G; Portella G
Recent Pat Anticancer Drug Discov; 2010 Nov; 5(3):219-41. PubMed ID: 20524930
[TBL] [Abstract][Full Text] [Related]
29. Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib).
Fei F; Lim M; Schmidhuber S; Moll J; Groffen J; Heisterkamp N
Mol Cancer; 2012 Jun; 11():42. PubMed ID: 22721004
[TBL] [Abstract][Full Text] [Related]
30. Identification of an Aurora kinase inhibitor specific for the Aurora B isoform.
Xie H; Lee MH; Zhu F; Reddy K; Peng C; Li Y; Lim DY; Kim DJ; Li X; Kang S; Li H; Ma W; Lubet RA; Ding J; Bode AM; Dong Z
Cancer Res; 2013 Jan; 73(2):716-24. PubMed ID: 23117881
[TBL] [Abstract][Full Text] [Related]
31. RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells.
Hata T; Furukawa T; Sunamura M; Egawa S; Motoi F; Ohmura N; Marumoto T; Saya H; Horii A
Cancer Res; 2005 Apr; 65(7):2899-905. PubMed ID: 15805292
[TBL] [Abstract][Full Text] [Related]
32. GSK1070916, a potent Aurora B/C kinase inhibitor with broad antitumor activity in tissue culture cells and human tumor xenograft models.
Hardwicke MA; Oleykowski CA; Plant R; Wang J; Liao Q; Moss K; Newlander K; Adams JL; Dhanak D; Yang J; Lai Z; Sutton D; Patrick D
Mol Cancer Ther; 2009 Jul; 8(7):1808-17. PubMed ID: 19567821
[TBL] [Abstract][Full Text] [Related]
33. Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models.
Diamond JR; Eckhardt SG; Tan AC; Newton TP; Selby HM; Brunkow KL; Kachaeva MI; Varella-Garcia M; Pitts TM; Bray MR; Fletcher GC; Tentler JJ
Clin Cancer Res; 2013 Jan; 19(1):291-303. PubMed ID: 23136197
[TBL] [Abstract][Full Text] [Related]
34. A comprehensive review on role of Aurora kinase inhibitors (AKIs) in cancer therapeutics.
Gupta D; Kumar M; Saifi S; Rawat S; Ethayathulla AS; Kaur P
Int J Biol Macromol; 2024 Apr; 265(Pt 2):130913. PubMed ID: 38508544
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells.
Borges KS; Castro-Gamero AM; Moreno DA; da Silva Silveira V; Brassesco MS; de Paula Queiroz RG; de Oliveira HF; Carlotti CG; Scrideli CA; Tone LG
J Cancer Res Clin Oncol; 2012 Mar; 138(3):405-14. PubMed ID: 22160182
[TBL] [Abstract][Full Text] [Related]
36. Small-molecule inhibition of Aurora kinases triggers spindle checkpoint-independent apoptosis in cancer cells.
Sun L; Li D; Dong X; Yu H; Dong JT; Zhang C; Lu X; Zhou J
Biochem Pharmacol; 2008 Mar; 75(5):1027-34. PubMed ID: 18163976
[TBL] [Abstract][Full Text] [Related]
37. ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatin.
Zhang L; Zhang S
J Obstet Gynaecol Res; 2011 Jun; 37(6):591-600. PubMed ID: 21159048
[TBL] [Abstract][Full Text] [Related]
38. Selective aurora kinase inhibitors identified using a taxol-induced checkpoint sensitivity screen.
Kwiatkowski N; Deng X; Wang J; Tan L; Villa F; Santaguida S; Huang HC; Mitchison T; Musacchio A; Gray N
ACS Chem Biol; 2012 Jan; 7(1):185-96. PubMed ID: 21992004
[TBL] [Abstract][Full Text] [Related]
39. Response of experimental malignant melanoma models to the pan-Aurora kinase inhibitor VE-465.
Pirker C; Lötsch D; Spiegl-Kreinecker S; Jantscher F; Sutterlüty H; Micksche M; Grusch M; Berger W
Exp Dermatol; 2010 Dec; 19(12):1040-7. PubMed ID: 21087322
[TBL] [Abstract][Full Text] [Related]
40. Paclitaxel and CYC3, an aurora kinase A inhibitor, synergise in pancreatic cancer cells but not bone marrow precursor cells.
Lin Y; Richards FM; Krippendorff BF; Bramhall JL; Harrington JA; Bapiro TE; Robertson A; Zheleva D; Jodrell DI
Br J Cancer; 2012 Nov; 107(10):1692-701. PubMed ID: 23037716
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
